24
19
1
49
2
2
2c
1b
1d
18
35
5a
1d
2 29
1d
25
Ronac Mamtani, MD, MSCE
78
5a
David J. Vaughn MD Associate Professor in GU Oncology
7
5f
Department: Medicine
4
1
b
1d
46
Contact information
4d
4
3
3
3
2
4
b
1f
4d
Division of Hematology Oncology
2e Perelman Center for Advanced Medicine
22 10th Floor, South Pavilion
16 Office #10-308
39 3400 Civic Center Blvd
Philadelphia, PA 19147
26
2e Perelman Center for Advanced Medicine
22 10th Floor, South Pavilion
16 Office #10-308
39 3400 Civic Center Blvd
Philadelphia, PA 19147
2c
Office: 2156627606
34 Fax: (215) 349-8551
24
99
34 Fax: (215) 349-8551
24
Email:
ronac.mamtani@uphs.upenn.edu
12
ronac.mamtani@uphs.upenn.edu
13
Education:
21 7 BS c
2b Cornell University, 2002.
21 7 MD 1e (Internal Medicine) c
37 Stony Brook School of Medicine, 2006.
21 7 MS 22 (Clinical Epidemiology) c
34 University of Pennsylvania , 2012.
c
3
3
3
3
8d
Permanent link21 7 BS c
2b Cornell University, 2002.
21 7 MD 1e (Internal Medicine) c
37 Stony Brook School of Medicine, 2006.
21 7 MS 22 (Clinical Epidemiology) c
34 University of Pennsylvania , 2012.
c
2 29
21
1e
1d
24
2b
29
27
23
157 Litt HK, Wodzinski A, Subramanian P, Donovan M, Vapiwala N, Narayan V, Mei L, Takvorian S, Haas NB, Parikh RB, Mistry R, Mamtani R.: OncoEducate: A Pilot Study of Generative AI to Enhance Patient-Clinician Communication in Genitourinary Cancer Care. Oncologist Apr 2026.
f0 Shen J, Linn KA, Clark AS, Mamtani R, Hubbard RA.: Missingness in Eligibility Criteria for Target Trial Emulation in EHR With Survival Outcomes. Stat Med 45, Apr 2026.
11a Litt H, Mehta P, Sahni A, Mamtani R.: FDA-authorized oncology artificial intelligence and machine learning devices and their clinical evidence: A cross-sectional analysis. J Cancer Policy 48: 100743, Apr 2026.
240 Galsky MD, Izadmehr S, Yu M, Curtis SD, Douville C, Popoli M, Ptak J, Dobbyn L, Silliman N, Chan KG, Dorff TB, Cetnar JP, O'Neil B, D'Souza A, Mamtani R, Kyriakopoulos CE, Brody R, Sadimin E, Mehrazin R, Chowell D, Sfakianos J, Daneshmand S, Pal SK, Bettegowda C, Kinzler KW, Papadopoulos N, Vogelstein B, Wang Y.: Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer. Proc Natl Acad Sci U S A 123: e2533449123, Feb 2026.
1c0 Litt HK, Wodzinski A, Subramanian P, Donovan M, Vapiwala N, Parikh RB, Narayan V, Mei L, Takvorian SU, Balzer Haas N, Mistry R, and Mamtani R.: OncoEducate: A pilot study of generative AI to support patient education in GU cancer care. 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium, San Fran, CA. 44(7): 713, Feb 2026 Notes: "Poster Presentation"
174 Squires P, Cook EE, Song Y, Wang CY, Zhang A, Seshasayee SM, Rogiers A, Li H, Mamtani R.: Treatment Patterns, Disease Recurrence, and Overall Survival in Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy: A Population-Level Claims-Based Analysis. Clin Genitourin Cancer Feb 2026.
172 Wang X, Long JB, Rothen J, Huang S, Soulos PR, Goldberg SB, Robinson TJ, Ma S, Mamtani R, Presley CJ, Wang SY, Kunst N, Gross CP, Dinan MA.: A Taxonomy for Assessing Real-World Targeted Cancer Therapy Options in the Context of Broad Genomic Profiling. J Natl Compr Canc Netw 24: e257131, Feb 2026.
d6 Chow RD, Sedhom R, Mamtani R.: Reduced-Dose Enfortumab Vedotin, Treatment Continuity, and Survival in Urothelial Cancer. JAMA Oncol Nov 2025.
f7 Litt HK, Mamtani R, Chow RD.: Outcomes of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer and severe renal dysfunction. Urol Oncol Nov 2025.
2c
7
1d
1f
Selected Publications
124 Martei YM, Chen K, Obasohan M, Mamtani R, Aakhus E, Shulman LN, Hubbard RA, Clark A.: Racial disparities and utilization trends of first-line targeted therapies for metastatic breast cancer. JNCI Cancer Spectr Apr 2026.157 Litt HK, Wodzinski A, Subramanian P, Donovan M, Vapiwala N, Narayan V, Mei L, Takvorian S, Haas NB, Parikh RB, Mistry R, Mamtani R.: OncoEducate: A Pilot Study of Generative AI to Enhance Patient-Clinician Communication in Genitourinary Cancer Care. Oncologist Apr 2026.
f0 Shen J, Linn KA, Clark AS, Mamtani R, Hubbard RA.: Missingness in Eligibility Criteria for Target Trial Emulation in EHR With Survival Outcomes. Stat Med 45, Apr 2026.
11a Litt H, Mehta P, Sahni A, Mamtani R.: FDA-authorized oncology artificial intelligence and machine learning devices and their clinical evidence: A cross-sectional analysis. J Cancer Policy 48: 100743, Apr 2026.
240 Galsky MD, Izadmehr S, Yu M, Curtis SD, Douville C, Popoli M, Ptak J, Dobbyn L, Silliman N, Chan KG, Dorff TB, Cetnar JP, O'Neil B, D'Souza A, Mamtani R, Kyriakopoulos CE, Brody R, Sadimin E, Mehrazin R, Chowell D, Sfakianos J, Daneshmand S, Pal SK, Bettegowda C, Kinzler KW, Papadopoulos N, Vogelstein B, Wang Y.: Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer. Proc Natl Acad Sci U S A 123: e2533449123, Feb 2026.
1c0 Litt HK, Wodzinski A, Subramanian P, Donovan M, Vapiwala N, Parikh RB, Narayan V, Mei L, Takvorian SU, Balzer Haas N, Mistry R, and Mamtani R.: OncoEducate: A pilot study of generative AI to support patient education in GU cancer care. 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium, San Fran, CA. 44(7): 713, Feb 2026 Notes: "Poster Presentation"
174 Squires P, Cook EE, Song Y, Wang CY, Zhang A, Seshasayee SM, Rogiers A, Li H, Mamtani R.: Treatment Patterns, Disease Recurrence, and Overall Survival in Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy: A Population-Level Claims-Based Analysis. Clin Genitourin Cancer Feb 2026.
172 Wang X, Long JB, Rothen J, Huang S, Soulos PR, Goldberg SB, Robinson TJ, Ma S, Mamtani R, Presley CJ, Wang SY, Kunst N, Gross CP, Dinan MA.: A Taxonomy for Assessing Real-World Targeted Cancer Therapy Options in the Context of Broad Genomic Profiling. J Natl Compr Canc Netw 24: e257131, Feb 2026.
d6 Chow RD, Sedhom R, Mamtani R.: Reduced-Dose Enfortumab Vedotin, Treatment Continuity, and Survival in Urothelial Cancer. JAMA Oncol Nov 2025.
f7 Litt HK, Mamtani R, Chow RD.: Outcomes of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer and severe renal dysfunction. Urol Oncol Nov 2025.
2c
44
23
Back to Top
1b
1d
18